Evolus (NASDAQ:EOLS) Shares Down 6.5% – Should You Sell?

Evolus, Inc. (NASDAQ:EOLS) was down 6.5% on Monday . The company traded as low as $13.06 and last traded at $13.06. Approximately 548,849 shares traded hands during mid-day trading, a decline of 41% from the average daily volume of 922,538 shares. The stock had previously closed at $13.97.

Analyst Ratings Changes

EOLS has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a research note on Tuesday, January 21st. Barclays increased their target price on Evolus from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, January 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Evolus in a research note on Wednesday, January 22nd.

Evolus Trading Down 7.1 %

The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The business’s fifty day simple moving average is $11.97 and its 200 day simple moving average is $13.90. The stock has a market cap of $821.89 million, a price-to-earnings ratio of -14.26 and a beta of 1.33.

Institutional Trading of Evolus

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its stake in shares of Evolus by 173.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock worth $6,781,000 after buying an additional 265,635 shares in the last quarter. Ikarian Capital LLC bought a new stake in Evolus during the third quarter worth approximately $4,184,000. Walleye Capital LLC acquired a new position in Evolus in the third quarter worth approximately $3,438,000. Lord Abbett & CO. LLC lifted its position in shares of Evolus by 23.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock valued at $16,126,000 after acquiring an additional 188,685 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Evolus in the 2nd quarter worth $1,326,000. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.